Form 4: ADMA Biologics Director Jerrold Grossman Reports Stock Transactions
SEC Form 4 Filing
Director Jerrold Grossman reports exercising options and selling shares of ADMA Biologics, Inc. common stock on August 29, 2024.
Summary
- On August 29, 2024, Jerrold B. Grossman, a director of ADMA Biologics, Inc., engaged in multiple transactions involving the company's common stock.
- Grossman exercised options to acquire 118,861 shares at $3.66, 9,000 shares at $5.96, and 9,000 shares at $10.8.
- He then sold 136,861 shares at a weighted average price of $17.2725, with prices ranging from $17.17 to $17.595.
- Following these transactions, Grossman directly owns 467,305 shares and indirectly owns additional shares through Brookwood LLC, the Jerrold Grossman 2019 Irrevocable Trust, Genesis Foundation Inc., and shares owned by his wife.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
This filing is a routine disclosure of stock transactions by a company insider, which is common in the biopharmaceutical industry. It provides transparency to investors regarding the actions of company leadership.
Comparison to Industry Standards
- Insider trading activity is a common occurrence in publicly traded companies, particularly in the pharmaceutical and biotechnology sectors.
- Monitoring insider transactions is a standard practice for investors to gauge management's sentiment and confidence in the company's future prospects.
- Comparable companies such as Grifols, CSL Behring, and Takeda also have similar insider transaction reporting requirements.
Stakeholder Impact
- The transactions may influence investor perception of ADMA Biologics.
- The sale of shares by a director could be interpreted in various ways by shareholders.
Key Dates
| Date | Description |
|---|---|
| 01/30/2015 | Options granted that vested in twenty-four equal monthly installments, becoming fully vested on January 30, 2017. |
| 01/28/2016 | Options granted that vested in twenty-four equal monthly installments, becoming fully vested on January 28, 2018. |
| 06/06/2017 | Options granted that vested in twenty-four equal monthly installments, becoming fully vested on June 6, 2019. |
| March 28, 2024 | Date of Limited Power of Attorney execution. |
| February 26, 2024 | Grant date of 12,020 restricted stock units which will vest in full on February 26, 2025. |
| 08/29/2024 | Date of stock option exercise and share sale transactions. |
| 08/30/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.